| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
L690330 targets inositol monophosphatase (IMPase), a magnesium-dependent enzyme that catalyzes the dephosphorylation of inositol monophosphate to inositol. IMPase is a key enzyme in the phosphatidylinositol (PI) signaling pathway, which is involved in cell signaling, membrane trafficking, and cytoskeletal organization. By inhibiting IMPase, L690330 reduces the availability of inositol for PI synthesis, leading to depletion of phosphatidylinositol and downstream signaling effects. L690330 is a competitive inhibitor with Ki values of 0.27 µM for recombinant human IMPase and 0.19 µM for recombinant bovine IMPase.
|
|---|---|
| ln Vitro |
L-690330 (50 μM; 1 hour) enhances p-AMPK and LC3-I/II expression in HEK293 cells and stimulates P-AMPK and autophagy in cells [2].
In vitro, L690330 potently inhibits IMPase activity from both recombinant and tissue sources. The compound has Ki values of 0.27 µM and 0.19 µM for recombinant human and bovine IMPase, respectively, and 0.30 µM and 0.42 µM for human and bovine frontal cortex IMPase. L690330 induces autophagy in COS-7 cells independently of mTOR inhibition. This effect is attributed to the depletion of inositol and the subsequent disruption of PI signaling, which activates autophagy through an mTOR-independent pathway. |
| ln Vivo |
L-690330 (intracerebroventricular injection; 0.1 μMol) They only lessen the amount of time in the light during the dark/light testing, but otherwise they had no influence on motor activity and coordination during beam walking [3].
In vivo, L690330 has been studied for its potential in the research of Huntington's disease. By inhibiting IMPase, the compound depletes inositol and modulates PI signaling, which may have therapeutic effects in neurodegenerative disorders. However, specific in vivo efficacy data are limited in the available literature. L690330 is stable to hydrolysis. |
| Enzyme Assay |
The non-cellular assay for L690330 involves measuring its inhibitory activity against IMPase using in vitro enzymatic assays. Recombinant human or bovine IMPase is incubated with inositol monophosphate substrate in the presence of varying concentrations of L690330. The release of inorganic phosphate is measured using a colorimetric assay (e.g., malachite green or ammonium molybdate). The inhibition of IMPase activity is calculated, and the Ki is determined from the inhibition curves.
|
| Cell Assay |
Western Blot analysis [2]
Cell Types: HEK293 cells Tested Concentrations: 50 μM Incubation Duration: 1 hour Experimental Results: Increased LC3-I/II and p-AMPK protein levels. The cellular assay for L690330 involves treating cultured cells (e.g., COS-7 cells) with the compound and measuring its effects on autophagy and cell signaling. Cells are treated with L690330 at various concentrations, and autophagy is assessed by measuring LC3-II levels by Western blotting or by using fluorescent autophagy reporters (e.g., GFP-LC3). The activation of autophagy is compared to that induced by mTOR inhibitors (e.g., rapamycin) to confirm the mTOR-independent mechanism. |
| Animal Protocol |
Animal/Disease Models: Eightweeks old male ICR mice [3]
Doses: 0.1 μmol Route of Administration: Intracerebroventricular injection Experimental Results: ICV injection will not affect the health of mice. In the in vivo efficacy study, L690330 is administered to animal models of Huntington's disease or other neurodegenerative disorders. The compound is typically administered by intraperitoneal injection or oral gavage. Behavioral assessments and histological examination of brain tissues are performed to evaluate the compound's effects on disease progression. However, specific published protocols for L690330 are limited. |
| ADME/Pharmacokinetics |
L690330 has a molecular weight of 298.12 and a molecular formula of C₈H₁₂O₈P₂. The compound is stable to hydrolysis. It should be stored as a powder at -20°C, protected from light and moisture. The compound is soluble in appropriate solvents for in vitro and in vivo studies. L690330 should be handled with appropriate laboratory safety precautions.
|
| Toxicity/Toxicokinetics |
The toxicological profile of L690330 has not been extensively characterized in the published literature. As an IMPase inhibitor, it may affect phosphoinositide signaling in multiple tissues. Comprehensive toxicology data are limited, and L690330 is not approved for clinical use. The compound should be handled with appropriate laboratory safety precautions.
|
| References |
|
| Additional Infomation |
[1-(4-hydroxyphenoxy)-1-phosphonoethyl]phosphonic acid is a 1,1-bis(phosphonic acid).
L690330 is a potent competitive inhibitor of inositol monophosphatase (IMPase) that has been used as a research tool to study the phosphatidylinositol signaling pathway. The compound induces autophagy independently of mTOR inhibition, making it a valuable tool for studying autophagy regulation. L690330 has also been studied for its potential in the research of Huntington's disease. The compound is not approved for clinical use and is strictly a research tool. |
| Molecular Formula |
C8H12O8P2
|
|---|---|
| Molecular Weight |
298.12
|
| Exact Mass |
298.001
|
| CAS # |
142523-38-4
|
| Related CAS # |
L-690330 hydrate
|
| PubChem CID |
132449
|
| Appearance |
White to off-white solid powder
|
| Density |
1.787g/cm3
|
| Boiling Point |
696.9ºC at 760mmHg
|
| Flash Point |
375.3ºC
|
| Vapour Pressure |
2.18E-20mmHg at 25°C
|
| Index of Refraction |
1.629
|
| LogP |
0.8
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
355
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JKOCAAWWDVHWKB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H12O8P2/c1-8(17(10,11)12,18(13,14)15)16-7-4-2-6(9)3-5-7/h2-5,9H,1H3,(H2,10,11,12)(H2,13,14,15)
|
| Chemical Name |
[1-(4-hydroxyphenoxy)-1-phosphonoethyl]phosphonic acid
|
| Synonyms |
L-690330; L 690330; L690330
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~33.33 mg/mL (~111.80 mM)
DMSO : ~25 mg/mL (~83.86 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.39 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (335.44 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3544 mL | 16.7718 mL | 33.5435 mL | |
| 5 mM | 0.6709 mL | 3.3544 mL | 6.7087 mL | |
| 10 mM | 0.3354 mL | 1.6772 mL | 3.3544 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
